All Outputs (6)

Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain (2023)
Journal Article
Muresan, P., Woodhams, S., Smith, F., Taresco, V., Shah, J., Wong, M., …Marlow, M. (2023). Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain. Nanomedicine: Nanotechnology, Biology and Medicine, 49, Article 102664. https://doi.org/10.1016/j.nano.2023.102664

We investigated how the biodistribution of cannabidiol (CBD) within the central nervous system (CNS) is influenced by two different formulations, an oil-in-water (O/W) nanoemulsion and polymer-coated nanoparticles (PCNPs). We observed that both CBD f... Read More about Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain.

Metabolic modeling-based drug repurposing in Glioblastoma (2022)
Journal Article
Tomi-Andrino, C., Pandele, A., Winzer, K., King, J., Rahman, R., & Kim, D. (2022). Metabolic modeling-based drug repurposing in Glioblastoma. Scientific Reports, 12, Article 11189. https://doi.org/10.1038/s41598-022-14721-w

The manifestation of intra- and inter-tumor heterogeneity hinders the development of ubiquitous cancer treatments, thus requiring a tailored therapy for each cancer type. Specifically, the reprogramming of cellular metabolism has been identified as a... Read More about Metabolic modeling-based drug repurposing in Glioblastoma.

CG7379 and ING1 suppress cancer cell invasion by maintaining cell–cell junction integrity (2021)
Journal Article
Rusu, A. D., Cornhill, Z. E., Coutiño, B. C., Uribe, M. C., Lourdusamy, A., Markus, Z., …Georgiou, M. (2021). CG7379 and ING1 suppress cancer cell invasion by maintaining cell–cell junction integrity. Open Biology, 11(9), Article 210077. https://doi.org/10.1098/rsob.210077

Approximately 90% of cancer-related deaths can be attributed to a tumour's ability to spread. We have identified CG7379, the fly orthologue of human ING1, as a potent invasion suppressor. ING1 is a type II tumour suppressor with well-established role... Read More about CG7379 and ING1 suppress cancer cell invasion by maintaining cell–cell junction integrity.

Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours (2020)
Journal Article
McCrorie, P., Mistry, J., Taresco, V., Lovato, T., Fay, M., Ward, I., …Rahman, R. (2020). Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours. European Journal of Pharmaceutics and Biopharmaceutics, 157, 108-120. https://doi.org/10.1016/j.ejpb.2020.10.005

Glioblastoma is a malignant brain tumour with a median survival of 14.6 months from diagnosis. Despite maximal surgical resection and concurrent chemoradiotherapy, reoccurrence is inevitable. To try combating the disease at a stage of low residual tu... Read More about Etoposide and olaparib polymer-coated nanoparticles within a bioadhesive sprayable hydrogel for post-surgical localised delivery to brain tumours.

Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential (2020)
Journal Article
Smith, S. J., Rowlinson, J., Estevez-Cebrero, M., Onion, D., Ritchie, A., Clarke, P., …Rahman, R. (2020). Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential. Neuro-Oncology Advances, 2(1), Article vdaa087. https://doi.org/10.1093/noajnl/vdaa087

Background Glioblastoma (GBM) is a highly aggressive brain tumor with rapid subclonal diversification, harboring molecular abnormalities that vary temporo-spatially, a contributor to therapy resistance. Fluorescence guided neurosurgical resection ut... Read More about Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential.

Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours (2017)
Journal Article
Haque, F., Varlet, P., Puntonet, J., Storer, L., Bountali, A., Rahman, R., …Grundy, R. G. (2017). Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathologica Communications, 5, 1-9. https://doi.org/10.1186/s40478-017-0449-1

Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a subset of adult glioblastoma... Read More about Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.